Q3 FY2026 · ended Sep 30, 2026 · Revenue $80.89M, +16.5% YoY · Filed Nov 5, 2026
Rigel Pharmaceuticals Inc (RIGL) files with the SEC under industry code 2834, Pharmaceutical Preparations. In Q3 of fiscal 2026, the quarter ended Sep 30, 2026, it reported revenue of $80.9 million and net income of $13.2 million. As of Sep 30, 2026 it held $120.7 million in cash and investments and $556,000 in total debt.
Revenue
$80.89M
+16.5% vs year-ago quarter
Net income
$13.19M
-52.7% vs year-ago quarter
Operating cash flow
$34.56M
+43.8% vs year-ago quarter
Free cash flow
—
EPS
$0.65
-55.5% vs year-ago quarter
Dividend per share
None
Shares outstanding
18.83M
+3.7% vs year-ago quarter
Net cash
$120.15M
Q3 FY2026
Operating margin
26.3%
TTM
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- RIGL (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- South San Francisco, CA
- SEC filer status
- Accelerated filer
- SEC CIK
- 1034842
- Former names
- RIGEL PHARMACEUTICALS INC (until Nov 5, 2026)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q3 FY2026 Sep 30, 2026 |
Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
|---|---|---|---|---|---|
| Revenue | $80.9M | $78.7M | $58.8M | $69.8M | $69.5M |
| Operating income | $17.1M | $23.6M | $11.9M | $23.2M | $28.4M |
| Net income | $13.2M | $17.3M | $8.7M | $268.1M | $27.9M |
| Diluted EPS | $0.65 | $0.88 | $0.44 | $13.27 | $1.46 |
| Operating cash flow | $34.6M | $30.7M | $2.7M | $22.0M | $24.0M |
| Total assets | $523.9M | $521.1M | $504.6M | $513.6M | $242.5M |
| Total liabilities | $78.8M | $95.6M | $104.7M | $122.1M | $124.9M |
| Stockholders' equity | $445.1M | $425.4M | $399.9M | $391.5M | $117.6M |
| Cash and investments | $120.7M | $95.3M | $146.7M | $155.0M | $137.1M |
| Total debt | $556,000 | $714,000 | $45.9M | $53.5M | $61.1M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Results of operations
|
Nov 5, 2026 | Nov 5, 2026 |
| 10-Q | Quarterly report | Nov 5, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 4, 2026 | Aug 4, 2026 |
| 10-Q | Quarterly report | Aug 4, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Officer or director change
|
Jul 1, 2026 | Jun 25, 2026 |
| 8-K |
Current report
Acquisition or sale of assets
|
Jun 17, 2026 | Jun 11, 2026 |
All 1002 Rigel Pharmaceuticals Inc SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.